Crystal form, salt form, composition and preparation method of pyridazine compound
Patent Information
- Application Number
- CN202380056182.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-05
- Filing Date
- 2023-08-01
- Publication Date
- 2025-03-21
AI Technical Summary
Existing NLRP3 inhibitors are not yet on the market. The preclinical compound MCC950 has a significant inhibitory effect, but no drug has yet passed clinical verification. The development of NLRP3 inhibitors has broad application prospects, but there are problems with complex preparation methods and difficulty in industrialization.
Provides crystal forms A, B and C of pyridazine compounds and their preparation methods. The crystal forms are determined through specific X-ray powder diffraction patterns and thermal analysis data, and the crystal forms are prepared with high physical and chemical stability. Compounds for the preparation of NLRP3 inhibitors.
It can effectively inhibit the activity of NLRP3 inflammasome and the activation of downstream caspase-1, inhibit the maturation and secretion of IL-1β, has good pharmacokinetic properties, and is suitable for the treatment of Parkinson's disease and Alzheimer's disease. and other related diseases.